Point-of-care liquid biopsy platform for rapid cancer detection with 99% accuracy and high sensitivity. Delivers non-invasive screening results in minutes, enabling early diagnosis across multiple cancer types at a lower cost than conventional test kits.
Manufactured by
Rapid Viral Detection Systems
Orlando FL, United States
Rapid Viral Detection Systems manufactures point-of-care viral screening devices utilizing saliva-based detection technology. The company's ViralStatDx system provides rapid diagnostic testing for respiratory and viral pathogens including COVID-19, Influenza A/B, Norovirus, and Nipah virus. Products are designed for decentralized healthcare settings requiring portable, non-invasive screening solutions.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Biopsense Oy
Finland · 3 relevant products
GeneCker Co., Ltd.
South Korea · 4 relevant products
Glycanostics, s.r.o.
Slovakia · 2 relevant products
58 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →12 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
3 of 94 closest product alternatives
Biopsense Oy · Finland
Liquid biopsy diagnostic solution for non-invasive cancer monitoring and treatment personalization through cell-free DNA analysis. Automates plasma separation, DNA extraction, and quantitation to reduce pre-analytical variability and enable frequent patient monitoring for improved treatment response assessment.
GeneCker Co., Ltd. · South Korea
Integrated platform for cancer diagnosis utilizing liquid biopsy techniques with CRISPR/Cas9 technology. Includes complete workflow from sample collection through DNA sequencing to result analysis.
Glycanostics, s.r.o. · Slovakia
Non-invasive liquid biopsy test for early-stage prostate cancer detection using glycan analysis in blood serum. Achieves up to 90% accuracy using magnetic particle-based technology with minimal blood sample requirement of 10 microliters.
91 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products